Abstract
Prostate tumors, resistant to current antiandrogen therapies, represent a serious clinical challenge. A new report identifies androgen-receptor-dependent liquid condensates as being responsible in part for therapeutic resistance, but, encouragingly, also reveals a novel vulnerability amenable to drug targeting.
Original language | English |
---|---|
Pages (from-to) | 1292-1293 |
Number of pages | 2 |
Journal | Nature Chemical Biology |
Volume | 18 |
Issue number | 12 |
Early online date | 13 Oct 2022 |
DOIs |
|
Publication status | Published - Dec 2022 |
Keywords
- cancer therapy
- cell signalling
- small molecules